Show simple item record

Acute administration of unacylated ghrelin has no effect on Basal or stimulated insulin secretion in healthy humans.

dc.contributor.author Benoit, SC
dc.contributor.author Bidlingmaier, M
dc.contributor.author D'Alessio, David A
dc.contributor.author Davis, HW
dc.contributor.author Haque, A
dc.contributor.author Summer, S
dc.contributor.author Tong, Jenny
dc.contributor.author Tschöp, MH
dc.coverage.spatial United States
dc.date.accessioned 2016-08-10T20:59:18Z
dc.date.issued 2014-07
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/24550190
dc.identifier db13-1598
dc.identifier.uri https://hdl.handle.net/10161/12642
dc.description.abstract Unacylated ghrelin (UAG) is the predominant ghrelin isoform in the circulation. Despite its inability to activate the classical ghrelin receptor, preclinical studies suggest that UAG may promote β-cell function. We hypothesized that UAG would oppose the effects of acylated ghrelin (AG) on insulin secretion and glucose tolerance. AG (1 µg/kg/h), UAG (4 µg/kg/h), combined AG+UAG, or saline were infused to 17 healthy subjects (9 men and 8 women) on four occasions in randomized order. Ghrelin was infused for 30 min to achieve steady-state levels and continued through a 3-h intravenous glucose tolerance test. The acute insulin response to glucose (AIRg), insulin sensitivity index (SI), disposition index (DI), and intravenous glucose tolerance (kg) were compared for each subject during the four infusions. AG infusion raised fasting glucose levels but had no effect on fasting plasma insulin. Compared with the saline control, AG and AG+UAG both decreased AIRg, but UAG alone had no effect. SI did not differ among the treatments. AG, but not UAG, reduced DI and kg and increased plasma growth hormone. UAG did not alter growth hormone, cortisol, glucagon, or free fatty acid levels. UAG selectively decreased glucose and fructose consumption compared with the other treatments. In contrast to previous reports, acute administration of UAG does not have independent effects on glucose tolerance or β-cell function and neither augments nor antagonizes the effects of AG.
dc.language eng
dc.relation.ispartof Diabetes
dc.relation.isversionof 10.2337/db13-1598
dc.subject Adolescent
dc.subject Adult
dc.subject Basal Metabolism
dc.subject Blood Glucose
dc.subject Drug Administration Schedule
dc.subject Female
dc.subject Ghrelin
dc.subject Health
dc.subject Humans
dc.subject Insulin
dc.subject Insulin-Secreting Cells
dc.subject Male
dc.subject Middle Aged
dc.subject Young Adult
dc.title Acute administration of unacylated ghrelin has no effect on Basal or stimulated insulin secretion in healthy humans.
dc.type Journal article
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/24550190
pubs.begin-page 2309
pubs.end-page 2319
pubs.issue 7
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Duke
pubs.organisational-group Duke Molecular Physiology Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Endocrinology, Metabolism, and Nutrition
pubs.organisational-group School of Medicine
pubs.publication-status Published
pubs.volume 63
dc.identifier.eissn 1939-327X


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record